POEMS Syndrome Market 2026

November 2025 | 219 pages | ID: P0F3E3BAC81BEN
DataM Intelligence

Abstracts

The POEMS Syndrome Market was valued at in and is anticipated to reach by , at a CAGR of 0.05 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the POEMS Syndrome Market.

This report delivers a comprehensive overview of the POEMS Syndrome Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding POEMS Syndrome Market. The POEMS Syndrome Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

POEMS Syndrome Market Scope:

By Diagnosis Type

• Electromyelogram (EMG)
• Blood and/or urine tests
• Imaging
• Physical exam
• Biopsy
• Others

By Treatment Type

• Chemotherapy
• Radiation therapy
• Physical therapy
• Others

By End-user

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Key Players

• Pfizer Inc.
• Bristol-Myers Squibb Company
• Baxter
• Genentech USA, Inc.
• Takeda Pharmaceuticals U.S.A., Inc.
• Oncopeptides AB
• Acrotech Biopharma, LLC.
• LGM PHARMA
• Jubilant Cadista Pharmaceuticals Inc.(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the POEMS Syndrome Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding POEMS Syndrome Market. The POEMS Syndrome Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Market Snippet by Diagnosis Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by End user
3.4. Market Snippet by Distribution channel
3.5. Market Snippet by Region

4. MARKET DYNAMICS

4.1. Market Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Innovation in the treatment of POEMS Syndrome is expected to drive market growth.
  4.1.2. Restraints:
    4.1.2.1. Lack of awareness of the disease among the population is expected to hamper in the forecast period.
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market
  6.1.1. Before COVID-19 Market Scenario
  6.1.2. Present COVID-19 Market Scenario
  6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. BY DIAGNOSIS TYPE

7.1. Introduction
  7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
  7.1.2. Market Attractiveness Index, By Diagnosis Type Segment
7.2. Electromyelogram (EMG)*
  7.2.1. Introduction
  7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Blood and/or urine tests
7.4. Imaging
  7.4.1. X-ray
  7.4.2. CT scan
  7.4.3. Others
7.5. Physical exam
7.6. Biopsy
7.7. Others

8. BY TREATMENT TYPE

8.1. Introduction
  8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Chemotherapy*
  8.2.1. Cyclophosphamide
  8.2.2. Pepaxto (melphalan flufenamide
  8.2.3. Others
  8.2.4. Introduction
  8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Radiation therapy
8.4. Physical therapy
8.5. Others

9. BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
  9.2.1. Introduction
  9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Centers
9.4. Ambulatory Surgical Centers
9.5. Others

10. BY DISTRIBUTION CHANNEL

10.1. Introduction
  10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacies*
  10.2.1. Introduction
  10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  11.1.2. Market Attractiveness Index, By Region
  11.1.3. North America
    11.1.3.1. Introduction
    11.1.3.2. Key Region-Specific Dynamics
    11.1.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    11.1.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    11.1.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    11.1.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    11.1.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      11.1.3.7.1. U.S.
      11.1.3.7.2. Canada
      11.1.3.7.3. Mexico
  11.1.4. Europe
    11.1.4.1. Introduction
    11.1.4.2. Key Region-Specific Dynamics
    11.1.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    11.1.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    11.1.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    11.1.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    11.1.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      11.1.4.7.1. Germany
      11.1.4.7.2. U.K.
      11.1.4.7.3. France
      11.1.4.7.4. Italy
      11.1.4.7.5. Spain
      11.1.4.7.6. Rest of Europe
  11.1.5. South America
    11.1.5.1. Introduction
    11.1.5.2. Key Region-Specific Dynamics
    11.1.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    11.1.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    11.1.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    11.1.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    11.1.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      11.1.5.7.1. Brazil
      11.1.5.7.2. Argentina
      11.1.5.7.3. Rest of South America
  11.1.6. Asia Pacific
    11.1.6.1. Introduction
    11.1.6.2. Key Region-Specific Dynamics
    11.1.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    11.1.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    11.1.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    11.1.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    11.1.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      11.1.6.7.1. China
      11.1.6.7.2. India
      11.1.6.7.3. Japan
      11.1.6.7.4. Australia
      11.1.6.7.5. Rest of Asia Pacific
  11.1.7. Middle East and Africa
    11.1.7.1. Introduction
    11.1.7.2. Key Region-Specific Dynamics
    11.1.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    11.1.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    11.1.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    11.1.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch

13. COMPANY PROFILES

13.1. Pfizer Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio and Description
  13.1.3. Key Highlights
  13.1.4. Financial Overview
13.2. Bristol-Myers Squibb Company
13.3. Baxter
13.4. Genentech USA, Inc.
13.5. Takeda Pharmaceuticals U.S.A., Inc.
13.6. Oncopeptides AB
13.7. Acrotech Biopharma, LLC.
13.8. LGM PHARMA
13.9. Jubilant Cadista Pharmaceuticals Inc.(*LIST NOT EXHAUSTIVE)

14. DATAM INTELLIGENCE

14.1. Appendix
14.2. About Us and Applications
14.3. Contact Us